Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. Department of Labor Supports Novartis Sales Reps In Their Overtime Suit

This article was originally published in The Pink Sheet Daily

Executive Summary

The federal government says a district court erred in finding sales reps are outside sales persons exempt from overtime pay requirements.

You may also be interested in...



Sales Reps Overtime Suit Goes To Supreme Court; Could The IMS Win Bite Pharma?

The high court will hear oral arguments on whether sales reps sell drugs or just promote them; Thomas Goldstein, who won a victory for PhRMA in Sorrell v. IMS, is representing the sales reps and former Solicitor General Paul Clement is arguing for GlaxoSmithKline.

Legal & Regulatory News, In Brief

Merck, SciClone join companies under Foreign Corrupt Practices Act investigation: Merck and SciClone reported in recent 10-Q filings with the Securities and Exchange Commission that the Department of Justice and the SEC are investigating their activities overseas to determine if they were in compliance with the Foreign Corrupt Practices Act. Merck said the DoJ and SEC are seeking information about its activities in a number of countries and SciClone said the agencies are investigating the "sale, licensing and marketing of its products in foreign countries, including China." Last year several companies, including Lilly, Bristol-Myers Squibb and AstraZeneca, reported they were under investigation for possible violations of the FCPA, which prohibits U.S. companies from bribing foreign officials for government contracts and other business (1"The Pink Sheet," Aug. 31, 2009)

Legal & Regulatory News, In Brief

Merck, SciClone join companies under Foreign Corrupt Practices Act investigation: Merck and SciClone reported in recent 10-Q filings with the Securities and Exchange Commission that the Department of Justice and the SEC are investigating their activities overseas to determine if they were in compliance with the Foreign Corrupt Practices Act. Merck said the DoJ and SEC are seeking information about its activities in a number of countries and SciClone said the agencies are investigating the "sale, licensing and marketing of its products in foreign countries, including China." Last year several companies, including Lilly, Bristol-Myers Squibb and AstraZeneca, reported they were under investigation for possible violations of the FCPA, which prohibits U.S. companies from bribing foreign officials for government contracts and other business (1"The Pink Sheet," Aug. 31, 2009)

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel